Patients with non-cystic fibrosis bronchiectasis (NCFBE) are subjected to higher healthcare costs after being diagnosed with Pseudomonas aeruginosa infection, a new study shows.
The study titled, “Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the US,” was published in the journal Medical Sciences.
NCFBE patients place a significant burden on the US healthcare system, with an estimated average cost to a US health plan of $4,862–$6,593 per patient, per year.
NCFBE is often characterized by recurrent infections, usually by the bacterial species P. aeruginosa. The prevalence of P. aeruginosa in this patient population is as high as 15-58%.
